Zanubrutinib joins the CLL treatment buffet.

Abstract

The advent of targeted therapies has transformed the treatment landscape of chronic lymphocytic leukaemia (CLL). Although chemoimmunotherapy constituted the standard of care in earlier decades, Bruton tyrosine kinase (BTK) inhibitors (ibrutinib and acalabrutinib), BCL2 inhibitors (venetoclax), and combinations thereof are currently the cornerstone of CLL management. With the intention of minimising off-target adverse effects, new BTK inhibitors, such as zanubrutinib and acalabrutinib, have been developed and approved for the treatment of several B-cell malignancies.